ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

Post author:Cleo Sciscioli
Post published:June 26, 2023
Post category:Newsroom

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).

You Might Also Like

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019

ERYTECH business update and financial results for the first half of 2014

ERYTECH Provides Business and Financial Update for the First Half of 2022